Monopar Accounts Payable vs Other Current Assets Analysis

MNPR Stock

USD 20.10 0.39 1.98%

Monopar Therapeutics financial indicator trend analysis is infinitely more than just investigating Monopar Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monopar Therapeutics is a good investment. Please check the relationship between Monopar Therapeutics Accounts Payable and its Other Current Assets accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.

Accounts Payable vs Other Current Assets

Accounts Payable vs Other Current Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monopar Therapeutics Accounts Payable account and Other Current Assets. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Monopar Therapeutics' Accounts Payable and Other Current Assets is 0.1. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Other Current Assets in the same time period over historical financial statements of Monopar Therapeutics, assuming nothing else is changed. The correlation between historical values of Monopar Therapeutics' Accounts Payable and Other Current Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Monopar Therapeutics are associated (or correlated) with its Other Current Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Assets has no effect on the direction of Accounts Payable i.e., Monopar Therapeutics' Accounts Payable and Other Current Assets go up and down completely randomly.

Correlation Coefficient

0.1

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Monopar Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Monopar Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most indicators from Monopar Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monopar Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Monopar Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.As of 11/22/2024, Selling General Administrative is likely to grow to about 3.4 B, while Tax Provision is likely to drop (67.7 K).

	2021	2022	2023	2024 (projected)
Total Operating Expenses	9.1M	10.5M	8.8M	7.5M
Research Development	6.5M	7.6M	5.6M	5.3M

Total Operating Expenses Research Development

Monopar Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Total Liab	Total Current Assets	Other Current Liab	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Common Stock Total Equity	Net Invested Capital	Net Working Capital	Common Stock	Capital Stock	Retained Earnings Total Equity	Short Long Term Debt Total
Total Assets		0.69	0.99	0.82	-0.72	0.69	0.98	-0.79	0.68	1.0	0.1	-0.97	-0.78	-0.78	1.0	0.46	0.86	0.33	0.84	0.66	0.61	0.69	0.61	0.61	0.05	-0.14
Total Current Liabilities	0.69		0.59	0.88	-0.86	1.0	0.56	-0.79	1.0	0.7	0.33	-0.55	-0.75	-0.77	0.7	0.8	0.83	0.1	0.89	0.82	0.16	0.24	0.86	0.85	0.36	-0.27
Total Stockholder Equity	0.99	0.59		0.76	-0.66	0.59	0.99	-0.75	0.59	0.99	0.06	-0.98	-0.74	-0.74	0.99	0.37	0.81	0.35	0.78	0.59	0.65	0.72	0.54	0.53	0.0	-0.11
Net Tangible Assets	0.82	0.88	0.76		-0.91	0.88	0.78	-0.86	0.88	0.83	0.42	-0.78	-0.84	-0.84	0.83	0.82	0.98	0.21	0.98	0.93	0.27	0.36	0.9	0.89	0.49	-0.3
Retained Earnings	-0.72	-0.86	-0.66	-0.91		-0.86	-0.67	0.9	-0.86	-0.74	-0.67	0.62	0.88	0.89	-0.75	-0.89	-0.91	-0.27	-0.96	-0.91	0.03	-0.07	-0.94	-0.94	-0.65	0.63
Accounts Payable	0.69	1.0	0.59	0.88	-0.86		0.56	-0.79	1.0	0.7	0.33	-0.55	-0.75	-0.77	0.7	0.8	0.83	0.1	0.89	0.82	0.16	0.24	0.86	0.85	0.36	-0.27
Cash	0.98	0.56	0.99	0.78	-0.67	0.56		-0.77	0.56	0.98	0.12	-0.99	-0.77	-0.76	0.98	0.41	0.83	0.36	0.79	0.64	0.64	0.71	0.57	0.57	0.09	-0.15
Other Assets	-0.79	-0.79	-0.75	-0.86	0.9	-0.79	-0.77		-0.79	-0.81	-0.46	0.74	1.0	1.0	-0.82	-0.71	-0.91	-0.43	-0.92	-0.82	-0.15	-0.26	-0.81	-0.81	-0.43	0.43
Total Liab	0.68	1.0	0.59	0.88	-0.86	1.0	0.56	-0.79		0.7	0.33	-0.55	-0.75	-0.77	0.7	0.79	0.83	0.1	0.89	0.82	0.16	0.24	0.85	0.85	0.35	-0.27
Total Current Assets	1.0	0.7	0.99	0.83	-0.74	0.7	0.98	-0.81	0.7		0.12	-0.97	-0.81	-0.8	1.0	0.47	0.87	0.34	0.85	0.67	0.6	0.67	0.63	0.63	0.07	-0.15
Other Current Liab	0.1	0.33	0.06	0.42	-0.67	0.33	0.12	-0.46	0.33	0.12		-0.04	-0.45	-0.45	0.15	0.76	0.4	0.01	0.48	0.63	-0.54	-0.48	0.7	0.72	0.95	-0.95
Net Debt	-0.97	-0.55	-0.98	-0.78	0.62	-0.55	-0.99	0.74	-0.55	-0.97	-0.04		0.74	0.73	-0.96	-0.38	-0.82	-0.35	-0.78	-0.62	-0.69	-0.76	-0.54	-0.53	-0.03	0.04
Non Current Assets Total	-0.78	-0.75	-0.74	-0.84	0.88	-0.75	-0.77	1.0	-0.75	-0.81	-0.45	0.74		1.0	-0.81	-0.68	-0.9	-0.48	-0.9	-0.8	-0.14	-0.25	-0.78	-0.78	-0.43	0.42
Non Currrent Assets Other	-0.78	-0.77	-0.74	-0.84	0.89	-0.77	-0.76	1.0	-0.77	-0.8	-0.45	0.73	1.0		-0.81	-0.69	-0.9	-0.46	-0.91	-0.8	-0.14	-0.24	-0.79	-0.79	-0.43	0.42
Cash And Short Term Investments	1.0	0.7	0.99	0.83	-0.75	0.7	0.98	-0.82	0.7	1.0	0.15	-0.96	-0.81	-0.81		0.48	0.87	0.32	0.85	0.68	0.58	0.66	0.64	0.64	0.09	-0.18
Common Stock Shares Outstanding	0.46	0.8	0.37	0.82	-0.89	0.8	0.41	-0.71	0.79	0.47	0.76	-0.38	-0.68	-0.69	0.48		0.74	0.07	0.83	0.91	-0.13	-0.06	0.97	0.97	0.81	-0.63
Capital Surpluse	0.86	0.83	0.81	0.98	-0.91	0.83	0.83	-0.91	0.83	0.87	0.4	-0.82	-0.9	-0.9	0.87	0.74		0.33	0.98	0.88	0.25	0.35	0.84	0.83	0.45	-0.31
Other Current Assets	0.33	0.1	0.35	0.21	-0.27	0.1	0.36	-0.43	0.1	0.34	0.01	-0.35	-0.48	-0.46	0.32	0.07	0.33		0.31	0.02	-0.01	0.05	0.05	0.05	-0.01	-0.02
Other Stockholder Equity	0.84	0.89	0.78	0.98	-0.96	0.89	0.79	-0.92	0.89	0.85	0.48	-0.78	-0.9	-0.91	0.85	0.83	0.98	0.31		0.91	0.2	0.3	0.91	0.9	0.5	-0.4
Common Stock Total Equity	0.66	0.82	0.59	0.93	-0.91	0.82	0.64	-0.82	0.82	0.67	0.63	-0.62	-0.8	-0.8	0.68	0.91	0.88	0.02	0.91		0.12	0.21	0.98	0.97	0.7	-0.5
Net Invested Capital	0.61	0.16	0.65	0.27	0.03	0.16	0.64	-0.15	0.16	0.6	-0.54	-0.69	-0.14	-0.14	0.58	-0.13	0.25	-0.01	0.2	0.12		0.99	0.02	0.0	-0.52	0.52
Net Working Capital	0.69	0.24	0.72	0.36	-0.07	0.24	0.71	-0.26	0.24	0.67	-0.48	-0.76	-0.25	-0.24	0.66	-0.06	0.35	0.05	0.3	0.21	0.99		0.11	0.09	-0.46	0.46
Common Stock	0.61	0.86	0.54	0.9	-0.94	0.86	0.57	-0.81	0.85	0.63	0.7	-0.54	-0.78	-0.79	0.64	0.97	0.84	0.05	0.91	0.98	0.02	0.11		1.0	0.74	-0.59
Capital Stock	0.61	0.85	0.53	0.89	-0.94	0.85	0.57	-0.81	0.85	0.63	0.72	-0.53	-0.78	-0.79	0.64	0.97	0.83	0.05	0.9	0.97	0.0	0.09	1.0		0.75	-0.63
Retained Earnings Total Equity	0.05	0.36	0.0	0.49	-0.65	0.36	0.09	-0.43	0.35	0.07	0.95	-0.03	-0.43	-0.43	0.09	0.81	0.45	-0.01	0.5	0.7	-0.52	-0.46	0.74	0.75		-0.8
Short Long Term Debt Total	-0.14	-0.27	-0.11	-0.3	0.63	-0.27	-0.15	0.43	-0.27	-0.15	-0.95	0.04	0.42	0.42	-0.18	-0.63	-0.31	-0.02	-0.4	-0.5	0.52	0.46	-0.59	-0.63	-0.8

Click cells to compare fundamentals

Monopar Therapeutics Account Relationship Matchups

Monopar Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	13.4M	16.9M	20.5M	13.2M	7.3M	11.5M
Total Current Liabilities	724.2K	1.2M	1.6M	3.1M	1.8M	1.1M
Total Stockholder Equity	12.6M	15.7M	18.9M	10.1M	5.6M	10.4M
Net Tangible Assets	6.9M	12.6M	15.7M	18.9M	21.8M	10.9M
Retained Earnings	(25.9M)	(32.2M)	(41.3M)	(51.8M)	(60.2M)	(57.2M)
Accounts Payable	724.2K	1.2M	1.6M	3.1M	1.8M	1.1M
Cash	13.2M	16.7M	20.3M	8.2M	7.3M	10.5M
Total Liab	724.2K	1.2M	1.6M	3.1M	1.8M	1.1M
Total Current Assets	13.2M	16.8M	20.5M	13.2M	7.3M	11.2M
Other Current Liab	724.2K	1.2M	1.6M	(48.6K)	1.8B	1.8B
Net Debt	(13.2M)	(16.7M)	(20.3M)	(8.2M)	(7.3M)	(7.6M)
Non Current Assets Total	0.0	122.4K	68.9K	61.2K	12.6K	12.0K
Cash And Short Term Investments	13.2M	16.7M	20.3M	13.1M	7.3M	12.2M
Common Stock Shares Outstanding	10.6M	11.0M	12.5M	12.7M	14.5M	12.7M
Liabilities And Stockholders Equity	13.4M	16.9M	20.5M	13.2M	7.3M	12.6M
Capital Surpluse	28.0M	28.6M	38.5M	47.9M	55.1M	32.5M
Other Current Assets	5.4K	62.7K	217.7K	46.0K	66.4K	99.5K
Other Stockholder Equity	38.5M	47.9M	60.2M	61.9M	65.8M	46.1M
Net Invested Capital	12.6M	15.7M	18.9M	10.1M	5.6M	5.3M
Net Working Capital	12.5M	15.6M	18.9M	10.0M	5.6M	5.3M
Common Stock	10.6K	11.5K	12.6K	12.9K	14.9K	12.7K
Accumulated Other Comprehensive Income	(11.0K)	(7.9K)	(3.2K)	8.9K	(14.1K)	(13.4K)
Capital Stock	10.6K	11.5K	12.6K	12.9K	14.9K	13.2K

Pair Trading with Monopar Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Monopar Stock

0.85	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.81	AGL	agilon health	Pair Corr
0.79	NKTX	Nkarta Inc	Pair Corr
0.78	MTEM	Molecular Templates	Pair Corr
0.77	ME	23Andme Holding	Pair Corr

The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.

The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Monopar Stock Analysis

When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC